Influence of personality disorder on the treatment of panic disorder--comparison study
Language English Country Sweden Media print
Document type Clinical Trial, Comparative Study, Journal Article
PubMed
16380683
PII: NEL260605A29
Knihovny.cz E-resources
- MeSH
- Agoraphobia complications therapy MeSH
- Alprazolam therapeutic use MeSH
- Anti-Anxiety Agents therapeutic use MeSH
- Adult MeSH
- Cognitive Behavioral Therapy * MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Personality Inventory MeSH
- Panic Disorder complications therapy MeSH
- Paroxetine therapeutic use MeSH
- Personality Disorders complications therapy MeSH
- Psychiatric Status Rating Scales MeSH
- Selective Serotonin Reuptake Inhibitors therapeutic use MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Comparative Study MeSH
- Names of Substances
- Alprazolam MeSH
- Anti-Anxiety Agents MeSH
- Paroxetine MeSH
- Serotonin Uptake Inhibitors MeSH
UNLABELLED: Most clinicians tend to believe that the occurrence of the anxiety disorder in comorbidity with a personality disorder often leads to longer treatment, worsens the prognosis, and thus increasing treatment costs. The study is designed to compare the short-term effectiveness of combination of cognitive behavioral therapy and pharmacotherapy in patient suffering with panic disorder with and without personality disorder. METHOD: We compare the efficacy of 6th week therapeutic program and 6th week follow up in patients suffering with panic disorder and/or agoraphobia and comorbid personality disorder (29 patients) and panic disorder and/or agoraphobia without comorbid personality disorder (31 patients). Diagnosis was done according to the ICD-10 research diagnostic criteria confirmed with MINI and support with psychological methods: IPDE, MCMI-III and TCI. Patients were treated with CBT and psychopharmacs. They were regularly assessed in week 0, 2, 4, 6 and 12 by an independent reviewer on the CGI (Clinical Global Improvement) for severity and change, PDSS (Panic Disorder Severity Scale), HAMA (Hamilton Anxiety Rating Scale), SDS (Sheehan Disability Scale), HDRS (Hamilton Depression Rating Scale), and in self-assessments BAI (Beck Anxiety Inventory) and BDI (Beck Depression Inventory). RESULTS: A combination of CBT and pharmacotherapy proved to be the effective treatment of patients suffering with panic disorder and/or agoraphobia with or without comorbid personality disorder. The 12th week treatment efficacy in the patients with panic disorder without personality disorder had been showed significantly better compared with the group with panic disorder comorbid with personality disorder in CGI and specific inventory for panic disorder--PDSS. Also the scores in depression inventories HDRS and BDI showed significantly higher decrease during the treatment comparing with group without personality disorder. But the treatment effect between groups did not differ in objective anxiety scale HAMA, and subjective anxiety scale BAI.